Krsnaa Diagnostics News, Corporate filings and Earnings/Conference Calls

Healthcare Services company Krsnaa Diagnostics announced Q1FY26 results Revenue from Operations: Rs 1,930 million compared to Rs 1,702 million during Q1FY25, change 13%. EBITDA: Rs 524 million compared to Rs 442 million during Q1FY25, change 19%. EBITDA Margin: 27% for Q1FY26. PAT: Rs 205 million compared to Rs 179 million during Q1FY25, change 15%. PAT Margin: 11% for Q1FY26. EPS: Rs 6.25 for Q1FY26. Yash Mutha, Managing Director, said: “We are delighted to share that Krsnaa Diagnostics has been awarded one of the most prestigious and transformative healthcare projects in the state of Rajasthan under the National Health Mission (NHM). After being on hold for some time, this critical project is now set in motion. This landmark initiative will enable us to deliver best-in-class diagnostic services to millions of citizens across the state, reinforcing our mission of making quality healthcare accessible to all. As part of this project, we will establish 42 state-of-the-art Mother Labs, 135 Satellite Labs, and over 1,300 Collection Centres, making it one of the largest and most comprehensive PPP diagnostic projects ever undertaken in India. The scale, reach, and impact of this tender underscore not just the trust placed in Krsnaa Diagnostics but also our proven ability to execute large-scale public health initiatives with excellence. It marks a defining growth milestone, one that will drive both strategic expansion and long-term value creation while making a meaningful difference in public health delivery. In Q1FY26, Krsnaa delivered a remarkable 13% YoY revenue growth, reaching Rs 1,930 million, driven by rising patient trust and growing brand awareness. Krsnaa Diagnostics has delivered breakout retail growth a 7.9x jump in revenue and a 6.7x surge in touchpoints in just 12 months, now spanning 2,414 locations across four states, we are fast emerging as India’s most formidable retail diagnostics growth story. Our services continue to gain traction, with significant increases in test volumes and patient footfall. EBITDA surged 19% YoY to Rs 524 million, supported by healthy margin expansion to 27%. Net profit climbed 15% YoY to Rs 205 million, with margins improving to 11% a reflection of our disciplined execution, operational efficiencies, and the strategic rollout of new centres. This consistent performance is a testament to our scalable model, strong governance, and operational agility, which position us to thrive in an evolving and high-growth healthcare ecosystem. Looking ahead, we are more energised and optimistic than ever. Backed by a seasoned and deeply committed leadership team, we are: Aggressively pursuing high-potential tenders across multiple states. Expanding into new geographies, through both PPP and our fast-growing RPL retail vertical. Strengthening our project pipeline to ensure sustained, predictable growth momentum. We are also making strategic investments in technology, automation, and digital transformation, unlocking faster turnaround times, seamless patient experiences, and future-ready operations. At Krsnaa Diagnostics, we are building more than a business; we are creating a healthcare movement that empowers communities, strengthens public health infrastructure, and generates long-term value for all stakeholders.” Pallavi Bhatevara, Executive Director, said: “At Krsnaa Diagnostics Limited, we remain unwavering in our mission to transform India’s diagnostic landscape by making high-quality, affordable, and technology-enabled diagnostic services available to every Indian regardless of geography, income, or infrastructure barriers. Diagnostics today are not just a support function in healthcare; they are the bedrock of effective treatment and prevention. With every test we perform, we enable quicker diagnoses, better outcomes, and healthier lives. And we take immense pride in being at the forefront of this transformation, not just participating in the growth of the industry, but leading it. It is with great pride and optimism that I share a landmark development in our growth journey, the successful execution of the Rajasthan Pathology tender agreement, one of the largest and most strategically significant public healthcare projects in India. This is healthcare infrastructure transformation at a population scale. It is a bold demonstration of Krsnaa’s unmatched execution capability, speed of deployment, and expertise in navigating complex healthcare ecosystems. With this project, we will touch millions of lives, enabling timely, affordable diagnostics in every corner of Rajasthan. The significance of this win goes far beyond numbers: It cements our leadership position in large-scale Public-Private Partnerships. It showcases our ability to build state-wide networks with speed, efficiency, and clinical excellence. It further validates the trust governments place in Krsnaa as their implementation partner of choice. This strategic milestone also significantly strengthens our long-term growth outlook. Our presence across Rajasthan is now comprehensive and deep-rooted, forming a robust platform for further expansion both in public healthcare and our fast-growing RPL retail brand. These initiatives are not just about expansion; they are about creating real impact. Whether it's through Public-Private Partnerships (PPP), state healthcare tenders, or direct-to-patient retail offerings under our RPL brand. We have consistently demonstrated our ability to deliver timely, technology-enabled, and patient-centric diagnostic solutions across urban, semi-urban, and rural India. As we continue to scale and deepen our presence, our core purpose remains unchanged: To be India’s most trusted and preferred diagnostics partner, delivering care that is affordable, dependable, and always within reach. We are excited about what lies ahead. With the Rajasthan project in motion, a strong national pipeline, and growing traction in both PPP and retail, Krsnaa Diagnostics is entering a new phase of accelerated, high-impact growth. And we are confident that we will continue to deliver long-term value to our patients, partners, and investors alike.” Result PDF

26.86% Fall from 52W High

Krsnaa Diagnostics News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Krsnaa Diagnostics from all sources in a single place.